8-K: Intelligent Bio Solutions Partners with Cliantha Research for Key Clinical Study

Intelligent Bio Solutions has partnered with Cliantha Research to conduct a pharmacokinetic study as part of its FDA 510(k) clinical study plan for its fingerprint drug screening system.

Summary

• Intelligent Bio Solutions (INBS) has announced a partnership with Cliantha Research to conduct a pharmacokinetic (PK) study.
• This study is a crucial part of INBS's FDA 510(k) clinical study plan for its Intelligent Fingerprinting Drug Screening System.
• The PK study will involve 40 healthy adult subjects and compare opiate levels in fingerprint sweat versus blood, oral fluid, and urine after drug administration.
• The study will use a validated liquid chromatography mass spectrometry (LC-MS/MS) method as the gold standard for comparison.
• The fingerprint sweat samples will be screened using INBS's system and compared to the LC-MS/MS results.
• The company received FDA guidance in June 2023, classifying their device as a Class II device requiring a 510(k) submission.
• The study aims to demonstrate that fingerprint sweat measurement is a reliable proxy for other sample types in detecting opiates.
• Subject recruitment is expected in March and April 2024, with the study beginning in May 2024 and sample analysis concluding by the end of June 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the progress in the FDA approval process and the partnership with a reputable CRO. The detailed timeline and clear objectives contribute to a sense of confidence.

Positives

• The partnership with Cliantha Research is a positive step in advancing the 510(k) pathway.
• The study will use a gold standard method (LC-MS/MS) for comparison, increasing the reliability of the results.
• The company has a clear timeline for the study, with recruitment, study start, and analysis completion dates.
• The company is progressing towards its goal of entering the US market with its innovative screening solution.

Risks

• The company's ability to successfully develop and commercialize its drug and diagnostic tests is subject to risks and uncertainties.
• The company's ability to secure regulatory approvals is not guaranteed.
• The company's expectations may prove to be materially different from the results expressed or implied by forward-looking statements.

Future Outlook

The company aims to remain on track for its planned entry into the US market and expand access to its innovative screening solution. The company is committed to executing its detailed plan for the clinical study.

Management Comments

• Harry Simeonidis, President and CEO, stated that initiating the clinical studies plan represents a critical milestone for the organization.
• Dr. Anne Marie Salapatek, Chief Scientific Officer at Cliantha Research, expressed excitement about commencing the clinical trial to test the innovative device.

Industry Context

This announcement is relevant to the medical technology industry, particularly in the area of drug screening and diagnostics. The partnership with a CRO like Cliantha Research is a common practice for companies seeking regulatory approval for medical devices. The focus on non-invasive testing aligns with a growing trend in the healthcare industry.

Comparison to Industry Standards

• The use of LC-MS/MS as a gold standard for comparison is consistent with industry best practices for pharmacokinetic studies.
• The study design, including the number of subjects (40) and the comparison of different sample types, is typical for a 510(k) submission.
• Other companies in the drug screening space, such as Abbott and Roche, also conduct rigorous clinical studies to validate their devices.
• The focus on fingerprint sweat analysis is a novel approach compared to traditional methods, potentially offering a more convenient and non-invasive solution.

Stakeholder Impact

• Shareholders will likely view this announcement positively as it represents progress towards commercialization.
• Employees may be motivated by the company's advancement in the regulatory process.
• Customers in the target markets (e.g., construction, manufacturing) may anticipate the availability of the new screening technology.
• Suppliers and partners may see this as a positive sign of the company's growth and potential.

Next Steps

• Recruitment and screening of subjects for the PK study in March and April 2024.
• Commencement of the PK study in May 2024.
• Completion of sample analysis by the end of June 2024.
• Continued progress on the FDA 510(k) pathway.

Key Dates

Keywords

Intelligent Bio Solutions, Cliantha Research, Pharmacokinetic Study, FDA 510(k), Fingerprint Drug Screening, Opiates, Clinical Study, LC-MS/MS, Medical Technology, Drug Screening